Citius Oncology, Inc. files 10-K Annual Report with SEC
Citius Oncology, Inc. has recently filed its 10-K Annual Report with the SEC, detailing the company’s financial performance and operations for the period ending September 30, 2024. The filing includes key documents such as the annual report, description of common stock, and the 2023 Omnibus Stock Incentive Plan. Investors and stakeholders can access the full filing on the SEC website for more detailed information.
Attachments:
1. Annual Report – Link
2. Description of Common Stock – Link
3. 2023 Omnibus Stock Incentive Plan – Link
Additionally, the filing includes documents such as the Insider Trading Policy and various certifications related to the company’s financial reporting. Citius Oncology, Inc. operates in the pharmaceutical preparations sector, with business addresses in New York and Cranford, NJ. Investors can review the full submission text file on the SEC website for a comprehensive overview of the company’s financial health.
Website: [Citius Oncology, Inc.](Insert Company Website Link)
Original Filing: Link to the Original Filing
